Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients
- PMID: 32593695
- DOI: 10.1016/j.clinre.2020.05.008
Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients
Abstract
Background: Transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients who are not suitable for surgical treatment. We aimed to investigate the treatment outcomes and comprehensive prognostic factors of CalliSpheres® microspheres (CSM) drug-eluting bead TACE (DEB-TACE) treatment and conventional TACE (cTACE) treatment in HCC patients.
Methods: Three hundred and thirty-five HCC patients received DEB-TACE or cTACE treatment were consecutively enrolled in multi-center, retrospective cohort study. Treatment response was conducted at M1, M3 or M6 after treatment. Progression free survival (PFS) and overall survival (OS) were recorded. Thirty-seven baseline factors including demographic characteristics, clinical features, biochemical indexes and previous treatment histories were selected.
Results: In total patients, history of drink and largest nodule size≥7cm independently predicted worse ORR, DEB-TACE predicted better OS, while largest nodule size≥7cm, increased Child-Pugh stage, ALB abnormal, ALP abnormal or AFP abnormal predicted worse survival. For DEB-TACE group, previous cTACE and ANC abnormal independently predicted worse ORR, and hepatic vein invasion, increased Child-Pugh stage or AFP abnormal independently predicted poor survival. For cTACE group, largest nodule size≥7cm independently predicted poor ORR, and multifocal disease as well as ALB abnormal predicted poor OS.
Conclusions: History of drink, largest nodule size≥7cm, DEB-TACE, increased Child-Pugh stage, abnormal ALB, ALP or AFP are potential prognostic factors in total patients, previous cTACE and ANC abnormal, hepatic vein invasion, increased Child-Pugh stage or AFP abnormal are potential prognostic factors in DEB-TA group, and largest nodule size≥7cm, multifocal disease and ALB abnormal are potential prognostic factors in cTACE group.
Keywords: Conventional transarterial chemoembolization; Drug-eluting bead-transarterial chemoembolization; Hepatocellular carcinoma; Prognostic factors; Survival; Treatment response.
Copyright © 2020. Published by Elsevier Masson SAS.
Similar articles
-
Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.J BUON. 2019 May-Jun;24(3):1150-1166. J BUON. 2019. PMID: 31424674
-
Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study.Cancer Manag Res. 2020 Feb 10;12:941-956. doi: 10.2147/CMAR.S187203. eCollection 2020. Cancer Manag Res. 2020. PMID: 32104076 Free PMC article.
-
5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis.Sci Rep. 2024 Oct 26;14(1):25588. doi: 10.1038/s41598-024-77531-2. Sci Rep. 2024. PMID: 39462077 Free PMC article.
-
Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis.Front Oncol. 2021 Mar 16;11:576232. doi: 10.3389/fonc.2021.576232. eCollection 2021. Front Oncol. 2021. PMID: 33796448 Free PMC article.
-
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma.Int J Mol Sci. 2020 Oct 31;21(21):8165. doi: 10.3390/ijms21218165. Int J Mol Sci. 2020. PMID: 33142892 Free PMC article. Review.
Cited by
-
Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching.World J Surg Oncol. 2025 Jan 24;23(1):21. doi: 10.1186/s12957-025-03679-4. World J Surg Oncol. 2025. PMID: 39856751 Free PMC article.
-
Development and Validation of a Vascular Endothelial Growth Factor A-associated Prognostic Model for Unresectable Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2023 Feb 5;10:139-156. doi: 10.2147/JHC.S399299. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36777498 Free PMC article.
-
Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization.J Hepatocell Carcinoma. 2023 Oct 24;10:1881-1895. doi: 10.2147/JHC.S422565. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 37901717 Free PMC article.
-
Clinical predictors for liver function impairment and post-embolization syndrome following transcatheter arterial chemoembolization in primary hepatic carcinoma patients: a retrospective study.Am J Cancer Res. 2025 May 15;15(5):2259-2274. doi: 10.62347/PJVG6340. eCollection 2025. Am J Cancer Res. 2025. PMID: 40520859 Free PMC article.
-
Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.Radiol Oncol. 2023 Feb 17;57(1):70-79. doi: 10.2478/raon-2023-0001. eCollection 2023 Mar 1. Radiol Oncol. 2023. PMID: 36794998 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous